Early Cancer Detection
Multi-cancer Early Detection (MCED)
R&D/Clinical StudiesProof-of-concept (ASCEND-LUNG)
Key Facts
Indication
Multi-cancer Early Detection (MCED)
Phase
R&D/Clinical Studies
Status
Proof-of-concept (ASCEND-LUNG)
Company
About Burning Rock Biotech
Burning Rock Biotech's mission is to 'Guard Life via Science' by becoming a new pillar in the international healthcare industry. The company has established itself as a leader in China's precision oncology diagnostics market, with a portfolio of CE-marked kits, a CLIA/CAP-certified lab, and a U.S. FDA Breakthrough Device designation. Its strategy is built on a dual business model of selling IVD products and providing LDT services, while strategically investing in R&D for early cancer detection and a nascent therapeutic pipeline to drive long-term growth.
View full company profileTherapeutic Areas
Other Multi-cancer Early Detection (MCED) Drugs
| Drug | Company | Phase |
|---|---|---|
| OneTest for Cancer | 20/20 BioLabs | Commercial |
| Multi-Omics Early Detection Platform | PrognomiQ | Discovery/Pre-Clinical |
| miONCO | Xgenera | Pre-clinical |